 33 PM / in 9 minutes BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated Reuters Staff 1 Min Read 
Jan 5 (Reuters) - Enanta Pharmaceuticals Inc: 
* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 
* ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED 
* ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY “INTREPID” OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED 
* ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage: